Todd A. Hardy

Prof. Dr. Todd A. Hardy


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in The Lancet Neurology
Verified
Journal Article
Closed access
THTodd A. Hardy
Todd A. Hardy
SRStephen W Reddel
Stephen W Reddel
MBMichael H Barnett
Michael H Barnett
JPJacqueline Palace
Jacqueline Palace
CLClaudia F Lucchinetti
Claudia F Lucchinetti
BWBrian G Weinshenker
Brian G Weinshenker

19 January 2013 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
THTodd A. Hardy
Todd A. Hardy
JCJeremy Chataway
Jeremy Chataway
Tumefactive lesions are an uncommon manifestation of demyelinating disease and can pose a diagnostic challenge in patients without a pre-existing diagnosis of multiple sclerosis. Choosing when to biopsy a tumefactive lesion to exclude alternative pathology can be difficult. Other questions include how best to treat an acute attack as well as the optimal timing of therapy to prevent relapse. This article aims to review the available literature for tumefactive demyelination and to propose an approach to diagnosis and management. We argue that disease modifying therapy should be considered for acute tumefactive demyelinating lesions only once criteria of dissemination in time and space are fulfilled and the diagnosis of multiple sclerosis is confirmed.

1 July 2014 in The Lancet Neurology
Verified
Journal Article
Closed access
THTodd A. Hardy
Todd A. Hardy
DMDavid H Miller
David H Miller

14 May 2024 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
BTBenjamin P Trewin
Benjamin P Trewin
RDRussell C. Dale
Russell C. Dale
JQJessica Qiu
Jessica Qiu
MCMelissa Chu
Melissa Chu
NJNiroshan Jeyakumar
Niroshan Jeyakumar
SRSudarshini Ramanathan
Sudarshini Ramanathan
Background: We sought to identify an optimal oral corticosteroid regimen at the onset of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), which would delay time to first relapse while minimising cumulative corticosteroid exposure.Methods: In a retrospective multicentre cohort study, Cox proportional hazards models examined the relationship between corticosteroid course as a time-varying covariate and time to first relapse. Simon-Makuch and Kaplan-Meier plots identified an optimal dosing strategy.Results: We evaluated 109 patients (62 female, 57%; 41 paediatric, 38%; median age at onset 26 years, (IQR 8–38); median follow-up 6.2 years (IQR 2.6–9.6)). 76/109 (70%) experienced a relapse (median time to first relapse 13.7 months; 95% CI 8.2 to 37.9). In a multivariable model, higher doses of oral prednisone delayed time to first relapse with an effect estimate of 3.7% (95% CI 0.8% to 6.6%; p=0.014) reduced hazard of relapse for every 1 mg/day dose increment. There was evidence of reduced hazard of relapse for patients dosed ≥12.5 mg/day (HR 0.21, 95% CI 0.07 to 0.6; p=0.0036), corresponding to a 79% reduction in relapse risk. There was evidence of reduced hazard of relapse for those dosed ≥12.5 mg/day for at least 3 months (HR 0.12, 95% CI 0.03 to 0.44; p=0.0012), corresponding to an 88% reduction in relapse risk compared with those never treated in this range. No patient with this recommended dosing at onset experienced a Common Terminology Criteria for Adverse Events grade >3 adverse effect.Conclusions: The optimal dose of 12.5 mg of prednisone daily in adults (0.16 mg/kg/day for children) for a minimum of 3 months at the onset of MOGAD delays time to first relapse.

31 March 2011 in Current Allergy and Asthma Reports
Verified
Journal Article
Closed access
PDF file
THTodd A. Hardy
Todd A. Hardy
SBStefan Blum
Stefan Blum
PMPamela Ann McCombe
Pamela Ann McCombe
SRStephen W. Reddel
Stephen W. Reddel

1 April 2016 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
THTodd A. Hardy
Todd A. Hardy
WTW Oliver Tobin
W Oliver Tobin
CLClaudia F Lucchinetti
Claudia F Lucchinetti
The availability of magnetic resonance imaging (MRI) has led to increasing recognition that multiple sclerosis (MS), tumefactive demyelination (TD) and Baló’s concentric sclerosis (BCS) share many overlapping features. Baló-like lesions, which exhibit limited features of BCS, may represent an intermediate between BCS and typical MS demyelination. Lesions labeled as tumefactive are typically larger, but otherwise have much in common with conventional MS lesions, and TD and BCS lesions can also overlap. In this article, we explore the similarities between typical MS, TD and BCS cases, and reflect on the potential insights that intermediate or overlapping phenotypes may contribute towards an understanding of MS immunopathogenesis, and question whether these atypical forms of demyelination should be classified as separate demyelinating diseases, as different lesional manifestations of demyelination of any cause or as part of a spectrum with conventional MS.